Recent Updates
Recently added Catalysts

Cyclosporine 0.010% eye

Phase 2

Laser In Situ Keratomileusis | Small molecule | Ophthalmology |AbbVie Inc.|Last Updated: Jul 11, 2013

Target and mechanism

ModalitySmall molecule

Also known as Cyclosporine 0.010% eye drops

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment621

FDA Designations

No designations recorded

Clinical trial landscape

Cyclosporine 0.010% eye · 1 trial · 1 indication

Phase 2 1
NCT00991458Study of Cyclosporine in Post-LASIK PatientsLaser In Situ Keratomileusis
COMPLETED621 Analytics
PHASE2COMPLETED
Study of Cyclosporine in Post-LASIK Patients
Laser In Situ KeratomileusisUnlock trial analytics

Study Endpoints

Primary Endpoints

Time to Cure
6 Months

Time to cure is defined as the number of days after laser in situ keratomileusis (LASIK) surgery that the patient has corneal sensitivity (the capability of the cornea to respond to stimulation) ≥ 50 millimeters in all 9 regions of both eyes after LASIK surgery. A patient is considered cured at the first of 2 consecutive visits meeting these criteria. The Inter-Quartile Range presented is actually the 25th Quantile and the 75th Quantile obtained from the Kaplan-Meier Model.

Secondary Endpoints

Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment
Months 3 to 6
Percentage of Patients With Cumulative Poor Vision
Month 3, Month 4, Month 5, Month 6
Worst Outcome Post-LASIK Surgery in Reading Speed Assessment
Months 3 to 6
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cyclosporine 0.010% eye dropsEXPERIMENTALCyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Cyclosporine 0.005% eye dropsEXPERIMENTALCyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Placebo (Vehicle for Cyclosporine)PLACEBO_COMPARATORPlacebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.

Interventions

NameTypeDescription
Cyclosporine 0.010% eye dropsDRUGCyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Cyclosporine 0.005% eye dropsDRUGCyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Placebo (Vehicle for Cyclosporine)DRUGPlacebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 50 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patient is scheduled for bilateral LASIK surgery * Patient is in good general health * Eye glasses prescription of -1 to -8 Exclusion Criteria: * Significant Dry Eye * Presence of eye disease * Uncontrolled systemic disease * Previous use of RESTASIS®

Countries:United States
Unlock Eligibility Criteria